Pyrimidine ring is the building unit of DNA and RNA and thus pyrimidine based chemical architectures
exhibit diverse pharmacological activities. Among the reported medicinal attributes of
pyrimidines, anticancer activity is the most extensively reported. The anticancer potential of pyrimidines in fused scaffolds
has also been evidenced through number of research article and patent literature. The pyrimidines based scaffolds have exerted
their cell killing effects through varied mechanisms which indicate their potential to interact with diverse enzymes/
targets/receptors. This review article strictly focuses on the patent literature from 2009 onwards. The structure of the
potent compounds, their IC50 values, models/assays used for the anticancer evaluation and the enzymes/ receptors/ targets involved
have been presented in this compilation. Significant number of patents i.e. 59 have been published on pyrimidine
based anticancer agents from 2009-2014 (from 2009 through the present date) which clearly indicate that this heterocycle is
an area of focus at present for researchers all over the globe. Moreover, out of the 59 patents published during this period, 32
have been published from 2012 onwards which further highlights the present interest of the researcher towards pyrimidine
based anticancer agents. The promising activity displayed by these pyrimidine based scaffolds clearly places them in forefront
as potential future drug candidates. The present compilation can be extremely beneficial for the medicinal chemists
working on design and synthesis of anticancer drugs.
Keywords: Anticancer, chemotherapeutic agents, heterocycles, medicinal, patent, pyrimidine.
Rights & PermissionsPrintExport